Research Journal of Pharmacy and Technology
SCOPUS
  • Year: 2022
  • Volume: 15
  • Issue: 7

Design, synthesis and antitubercular study of novel pyrazoline moiety as mycobacterium tuberculosis shikimate kinase inhibitor

  • Author:
  • P Deepika*,1,4, D. Uma Maheshwari2, M. Kumar2, B. S. Venkateswarlu2, K. R Vimal3
  • Total Page Count: 3
  • Page Number: 2895 to 2897

1Ph.D Research Scholar, Department of Pharmaceutical Chemistry, Vinayaka Missions College of Pharmacy, Salem, Tamil Nadu, India

2Professor, Vinayaka Missions College of Pharmacy, Salem, Tamil Nadu, India - 636008

3Assistant Professor, Devaki Amma Memorial College of Pharmacy, Chelembra, Malappuram - 673634

4Associate Professor, Jamia Salafiya Pharmacy College, Pulikkal, Malappuram, Kerala - 673637

*Corresponding Author E-mail: deepikaprasannakumar@gmail.com

Online published on 21 February, 2023.

Abstract

A series of pyrazoline comprising coumarin moiety was docked against Mycobacterium tuberculosis shikimate kinase which is an essential target for novel anti tubercular drug design. When the designed pyrazoline containing coumarin derivatives were docked with the receptor (1U8A), the docking scores obtained were greater than the natural ligand and the standards of some derivatives. A number of substituted chalcones were synthesized from thiophene-2-carboxaldehyde by condensing with various substituted acetophenones in presence of sodium hydroxide as a base. Pyrazoline derivatives were prepared by the condensation of chalcones with coumarin carbohydrazide in the presence of ethanol as the catalyst. The structures of the final synthesized compounds were confirmed by spectral analysis. Analogue 3a showed profound antitubercular activity against the organism at lower concentration.

Keywords

Antitubercular, Chalcone, Coumarin, Carbohydrazide, Pyrazoline, Shikimate kinase